Carl Edward Gulbrandsen

7655259, Feb 2, 2010

Feb 2, 2007

11/670671

Austin L. Shug - Madison WI, US
Carl E. Gulbrandsen - Madison WI, US

SIGMA-TAU Industrie Farmaceutiche Riunite S.p.A - Rome

A61K 9/16
A61K 9/14
A61K 9/48
A61K 9/52
A61K 9/20
A61K 9/22

424490, 424451, 424457, 424464, 424468, 424489, 424497

A sustained release, orally administered pharmaceutical composition comprising carnitine and an acceptable pharmaceutical excipient is described for the treatment of carnitine deficiency and other carnitine responsive conditions. The sustained release formulation avoids the characteristic problems of gastrointestinal invitation, dumping in the urine and bacterial degradation attendant previously known oral formulations of carnitine.

20030170290, Sep 11, 2003

Mar 7, 2003

10/384085

Austin Shug - Madison WI, US
Carl Gulbrandsen - Madison WI, US

A61K031/205
A61K009/16
A61K009/50

424/428000, 514/556000

A sustained release, orally administered pharmaceutical composition comprising carnitine and an acceptable pharmaceutical excipient is described for the treatment of carnitine deficiency and other carnitine responsive conditions. The sustained release formulation avoids the characteristic problems of gastrointestinal invitation, dumping in the urine and bacterial degradation attendant previously known oral formulations of carnitine.

20060013887, Jan 19, 2006

Sep 9, 2005

11/223086

Austin Shug - Madison WI, US
Carl Gulbrandsen - Madison WI, US

A61K 9/22
A61K 9/16
A61K 9/50

424490000, 424468000

A sustained release, orally administered pharmaceutical composition comprising carnitine and an acceptable pharmaceutical excipient is described for the treatment of carnitine deficiency and other carnitine responsive conditions. The sustained release formulation avoids the characteristic problems of gastrointestinal invitation, dumping in the urine and bacterial degradation attendant previously known oral formulations of carnitine.

57007900, Dec 23, 1997

Jan 17, 1996

8/588067

Carl E. Gulbrandsen - Madison WI
Richard L. Moss - Middleton WI

Bone Care International, Inc. - Madison WI

A61K 3159

514167

Method of increasing the strength of contraction in the mammalian heart muscle by administering to the mammal an effective amount of an activated Vitamin D compound, i. e. a 1. alpha. -hydroxylated Vitamin D compound which binds with the Vitamin D receptor and produces a positive inotropic effect in the heart muscle. The activated Vitamin D compound may be given as a means to prevent myocardial failure or to treat myocardial failure.

53507452, Sep 27, 1994

Jan 29, 1993

8/010823

Carl E. Gulbrandsen - Madison WI
Richard L. Moss - Middleton WI

Lunar Corporation - Madison WI

A61K 3159

514167

Method of increasing the strength of contraction in the mammalian heart muscle by administering to the mammal an effective amount of an activated Vitamin D compound, i. e. a 1. alpha. -hydroxylated Vitamin D compound which binds with the Vitamin D receptor and produces a positive inotropic effect in the heart muscle. The activated Vitamin D compound may be given as a means to treat myocardial failure.